J&J: positive CHMP opinion for Ponvory
(CercleFinance.com) - Johnson & Johnson's Janssen Pharmaceutical Companies today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Ponvory (ponesimod) for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS).
"Relapsing forms of multiple sclerosis (MS) have varied and often unpredictable symptoms, posing a unique human, societal and economic burden", said Catherine Taylor, vice president at Johnson & Johnson Middle East.
"If approved by the European Commission, ponesimod has the potential to help more people living with relapsing forms of MS," she added.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
"Relapsing forms of multiple sclerosis (MS) have varied and often unpredictable symptoms, posing a unique human, societal and economic burden", said Catherine Taylor, vice president at Johnson & Johnson Middle East.
"If approved by the European Commission, ponesimod has the potential to help more people living with relapsing forms of MS," she added.
Copyright (c) 2021 CercleFinance.com. All rights reserved.